
    
      The intervention will involve administration of external beam radiotherapy (5 fractions of
      2Gy) focused to the heart.

      Measurements of effect will be assessed at 12 weeks by:

      Amyloid PET Cardiac MRI with administration of gadolinium and ultrasound A blood venous
      sample (cardiac biomarkers) Quality of life assessments
    
  